Patients with non-alcoholic fatty liver disease are characterised by a decreased n-3/n-6
polyunsaturated fatty acid (PUFA) ratio in hepatic phospholipids. The metabolic …

Background There are only few data relating the metabolic consequences of feeding diets
very low in n-3 fatty acids. This experiment carried out in mice aims at studying the impact of …

Background Low hepatic content of n-3 PUFA has been associated with NAFLD in humans.
Whether this is associated with reduced dietary intake or increased turnover of these FA is …

Dietary n-3 polyunsaturated fatty acids (n-3 PUFAs) have well-documented protective effects
against obesity-induced insulin resistance and hepatic steatosis. Here, we investigated the …

Obese and type 2 diabetic (T2DM) patients have a high prevalence of nonalcoholic fatty liver
disease (NAFLD). NAFLD is a continuum of chronic liver diseases ranging from benign …

The prevalence of non-alcoholic fatty liver disease (NAFLD) has increased in parallel with
central obesity and is now the most common chronic liver disease in developed countries …

Dietary polyunsaturated fatty acids (PUFA) are increasingly recognized for their health
benefits, whereas a high production of endogenous fatty acids–a process called de novo …

Patients with non-alcoholic fatty liver disease (NAFLD) have an increased risk for
progression to hepatocellular carcinoma in addition to comorbidities such as cardiovascular …

Deficiency of polyunsaturated fatty acids (PUFAs) is known to induce hepatic steatosis.
However, it is not clearly understood which type of PUFA is responsible for the worsening of …

Leptin-deficient ob/ob mice show many characteristics of obesity, including excess
peripheral adiposity as well as severe hepatic steatosis, at least in part, due to increased …